MOG antibodies B cells CRMP5 Ependymal cell Amino acid Disease modifying treatments Animal model Anti-GFAP encephalomyelitis Bone Estradiol Circadian clock Perceptual learning Microglia Collapsing response mediator protein MOGAD Immune checkpoint inhibitors Neuromyelitis optica spectrum disorders NMOSD GSK-3β Pallidin Neurite outgrowth Myelitis Disease-modifying treatments Neuromyelitis optica MRI GABA Adverse events Bright Neuromyelitis optica spectrum disorders Autoimmune diseases Progesterone Myelin oligodendrocyte glycoprotein Encephalitis Glutamate CP Neuroscience Database Clinically isolated syndrome CIS Breastfeeding Optic neuritis ON Blood-brain barrier Neuraxial analgesia ERRα COVID-19 Cancer Neuroinflammation Olfaction Multiple sclerosis MS Biobank LAT1 Neural antibodies Autoantibodies Blood brain barrier Cannabinoid receptor type 2 Autoimmune encephalitis Post-partum Multiple sclerosis Longitudinally extensive transverse myelitis Reproductive assistance Aquaporin-4 antibody Glia Biomarkers Microenvironment Endocannabinoid system Drosophila Neuromyelitis optica spectrum disorder Aquaporin-4-IgG AQP4-IgG Hippocampus Cilia Phosphorylation MOG Cannabinoid receptor type 2 Endocannabinoid system Microglia Neuroinflammation Area postrema syndrome Connexins Registry Demyelination MOG-IgG associated disorders MOGAD Ependymal cell neuromyelitis optica aquaporin-4 cilia sub-ventricular zone Rituximab Relapses CP Molecular biology Pregnancy Prognosis Optic neuritis Immunosuppressant Paraneoplastic neurological syndromes Nonactive multiple sclerosis Neurological immune-related adverse events CD14 Children Treatment response Cancer immunotherapy Optogenetic Prognostic factors Lateral diffusion Aquaporin-4 antibodies Central nervous system NMOSD Neuromyelitis optica spectrum disorder T follicular helper cells T follicular regulatory cells B cells rituximab Aquaporin-4 Astrocyte Adult neurogenesis